<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00143351</url>
  </required_header>
  <id_info>
    <org_study_id>A1281088</org_study_id>
    <nct_id>NCT00143351</nct_id>
  </id_info>
  <brief_title>Mozart Relapse Study</brief_title>
  <official_title>Open Extension Study Evaluating the Long-term Efficacy, Safety, and Tolerability of Oral Ziprasidone in the Treatment of Resistant/Intolerant Schizophrenic Patients Who Have Acutely Responded to Ziprasidone in the Mozart Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer's Upjohn has merged with Mylan to form Viatris Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of&#xD;
      resistant schizophrenic subjects who have benefited from participation in the phase III&#xD;
      ziprasidone study A1281039 (MOZART study), to assess the efficacy of ziprasidone in the&#xD;
      relapse prevention of schizophrenia, to collect long-term data on safety and tolerability of&#xD;
      oral Ziprasidone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>long-term efficacy of oral Ziprasidone in the maintenance treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of ziprasidone in the relapse prevention of schizophrenia To collect long-term data on safety and tolerability of oral Ziprasidone</measure>
  </secondary_outcome>
  <enrollment>75</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have completed MOZART study and who are responders to Ziprasidone:&#xD;
&#xD;
          -  Responders: patients with a 20% or more reduction in the PANSS total score at the&#xD;
             endpoint of the Mozart Study (recorded at V18 in the Mozart) as compared with the&#xD;
             baseline value&#xD;
&#xD;
          -  Patients not hospitalised in an acute psychiatric service&#xD;
&#xD;
          -  Written, informed consent to participation.&#xD;
&#xD;
          -  Female patients of at risk of pregnancy must avoid to remain pregnant; if already&#xD;
             used, an adequate method of contraception can be continued&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric:&#xD;
&#xD;
          -  Subjects with a score of greater than or equal to 5 and an increase of at least 2&#xD;
             points (with respect to baseline value of MOZART study) at one of the following PANSS&#xD;
             items: P7 (hostility), G8 (uncooperativeness) or G14 (poor control impulse)&#xD;
&#xD;
          -  Subjects with a score equal to 3 and an increase of at least 1 point (with respect to&#xD;
             baseline value of MOZART study) at item 8 (suicide) of CDSS&#xD;
&#xD;
          -  General:&#xD;
&#xD;
          -  Patients who, during MOZART study, have developed one of the following diseases will&#xD;
             be excluded: (or patients who do not satisfy anymore one of the following general&#xD;
             exclusion criteria of MOZART study)&#xD;
&#xD;
          -  Subjects with a history of clinically significant and/or currently relevant&#xD;
             haematological, renal (including single kidney), hepatic, gastrointestinal, endocrine&#xD;
             (except for current adequately treated hypo- or hyperthyroidism), pulmonary (excluding&#xD;
             chronic bronchitis, mild emphysema or chronic obstructive pulmonary disease),&#xD;
             dermatological, oncological, or neurological disease, excluding tardive dyskinesia but&#xD;
             including all forms of epilepsy (febrile convulsions in childhood acceptable). The&#xD;
             only subjects with known prior malignant disease who are eligible are those with cured&#xD;
             prior skin cancer. Controlled Type II diabetes (glucose &lt; 180 mg/100 ml at screening&#xD;
             and baseline with dietary or oral hypoglycemic treatment) will not be considered a&#xD;
             significant medical illness and would not exclude a subject from the study&#xD;
&#xD;
          -  Patients with a non stabilized somatic disease - Acute or chronic heart disease&#xD;
&#xD;
          -  Clinically significant ECG abnormalities&#xD;
&#xD;
          -  Subjects with QTc greater than or equal to 500 msec (subjects with QTc greater than or&#xD;
             equal to 450 msec and &lt; 500 msec should be discussed with the cardiologist) -&#xD;
             Concomitant treatment with medications that prolong QTc interval (please review&#xD;
             prescribing information of other treatments)&#xD;
&#xD;
          -  Subjects with serum K+ outside the normal range&#xD;
&#xD;
          -  History of seizure (should be discussed with the Sponsor)&#xD;
&#xD;
          -  Subject with any confirmed laboratory values that deviate from the upper or lower&#xD;
             limits of normal prior to study entry, except for clinically insignificant deviations&#xD;
             as determined by investigator&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Subjects who intend to donate blood or blood products during the 4 weeks prior to the&#xD;
             study, during the study or in the 30 days after the study ends&#xD;
&#xD;
          -  Subjects unable or unlikely to follow the study protocol&#xD;
&#xD;
          -  Subjects with a history of neuroleptic malignant syndrome developing from the&#xD;
             administration of antipsychotic compounds&#xD;
&#xD;
          -  Diagnosis of substance dependence using DSM-IV criteria (305.xx)&#xD;
&#xD;
          -  Positive urine drug screen at screening for amphetamines, cocaine or opioids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vicenza</city>
        <state>Bassano DEL Grappa</state>
        <zip>36061</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Citta' Di Castello</city>
        <state>Perugia</state>
        <zip>06012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bari</city>
        <zip>70100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guardiagrele (CH)</city>
        <zip>66016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Messina</city>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trieste</city>
        <zip>34126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Verona</city>
        <zip>37100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

